Eliquis (apixaban) is the most prescribed blood thinner in the United States and is covered by virtually all insurance plans for its approved indications (atrial fibrillation, DVT/PE treatment and prevention). As one of the highest-revenue drugs in the country, Eliquis remains a brand-name medication with no generic available yet. The Inflation Reduction Act's Medicare price negotiation may impact Eliquis pricing.
Key Facts
Check Your Specific Plan's Formulary
Coverage varies by plan. Use our formulary checker tool to look up your exact copay and restrictions.
Open Formulary CheckerFrequently Asked Questions
As of 2026, there is no FDA-approved generic version of Eliquis (apixaban). Patent litigation settlements suggest generic entry may occur in the 2028 to 2031 timeframe. In the meantime, the IRA-negotiated Medicare price and manufacturer copay programs help reduce costs.
Eliquis costs on Medicare Part D vary by plan, but the $2,000 annual out-of-pocket cap means your total drug spending is limited. Eliquis was among the first drugs selected for Medicare price negotiation under the IRA. The negotiated price, effective in 2026, should reduce overall plan costs and potentially lower beneficiary copays.
Yes. BMS offers the Eliquis 360 Support program with a copay card for commercially insured patients (as low as $10/month). For uninsured or underinsured patients, the BMS Access Support program may provide Eliquis at no cost. Medicare patients cannot use manufacturer copay cards but may qualify for Extra Help (LIS).
Related Resources
- Medicare Part D Formulary 2026
- UnitedHealthcare Formulary 2026
- Aetna Formulary 2026
- Xarelto cash price comparison on RxGrab
- Warfarin cash price comparison on RxGrab
- Pradaxa cash price comparison on RxGrab
- Savaysa cash price comparison on RxGrab
- Heparin cash price comparison on RxGrab
- Xarelto patient assistance program
- Warfarin patient assistance program
- Pradaxa patient assistance program
- Drug interaction checker tool
- Patient assistance program finder
Get Formulary and Coverage Updates
Subscribe to receive alerts on formulary changes, new drug approvals, and insurance coverage updates.